Small molecule inhibitors of necrosis

ABSTRACT

The invention features methods for decreasing necrosis. The invention also features methods for treating a subject with a condition in which necrosis occurs. The invention further features chemical compounds used to decrease necrosis.

CROSS REFERENCE TO RELATED APPLICATIONS

This application claims priority from U.S. Provisional Application Ser.Nos. 60/159,668, filed Oct. 15, 1999 and 60/174,749, filed Jan. 6, 2000which claims benefit of 60/159,668 Oct. 15, 1999.

BACKGROUND OF THE INVENTION

In general, the invention relates to methods and compounds used todecrease necrosis.

In many diseases, cell death is mediated through apoptotic and/ornecrotic pathways. While much is known about the mechanisms of actionthat control apoptosis, control of necrosis is not as well understood.Understanding the mechanisms regulating both necrosis and apoptosis incells is essential to being able to treat conditions, such asneurodegenerative diseases, stroke, coronary heart disease, kidneydisease, and liver disease. A thorough understanding of necrotic andapoptotic cell death pathways is also crucial to treating AIDS and theconditions associated with AIDS, such as retinal necrosis.

Research has shown that caspases play a central role in the induction ofapoptosis. Peptide based inhibitors of caspases, such as zVAD-fmk areuseful in preventing activation of the apoptotic cell death pathway incells stimulated to undergo apoptosis by compounds such as TNFα.However, cells treated with zVAD-fmk and these cell death stimuli stilldie through a caspase-independent form of necrosis.

Discovery of a compound which prevents caspase-independent cell death(necrosis) would provide a useful therapeutic for treating conditions inwhich necrosis occurs, and for preventing the onset of necrosis. Thesecompounds and methods may be particularly useful for treating ischemicbrain and heart injuries and head traumas.

SUMMARY OF THE INVENTION

The present invention features methods and compounds for decreasingnecrosis. The compounds of the present invention may be used astherapeutics to decrease necrosis in a desired cell, such as a neuron.These compounds are characterized by their ability to decrease necrosisin response to modulation of intracellular signaling pathways, such asthose activated by TNFα. By also treating the cells with zVAD-fmk, wehave inhibited the apoptotic pathway. Accordingly, we have been able todetermine that the compounds of the invention specifically decreasenecrosis. In addition, we have shown that the identified compounds thatdecrease necrosis in response to a necrotic pathway activated byzVAD-fmk and TNFα, also decrease necrosis in response to a necroticpathway activated by zVAD-fmk and dimethyl sulfoxide (DMSO).

Accordingly, in a first aspect, the invention features a chemicalcompound in a pharmaceutically acceptable carrier, having the formula:

wherein each R₁ is independently selected from the group consisting ofhydrogen, carboxy, methyl, hydroxyl, methoxyl, amino, and nitro; R₂ isselected from the group consisting of hydrogen, alkyl, and acyl; R₃ isselected from the group consisting of alkyl, acyl, halogen, hydrogen, orhydroxyl; R₄ is selected from the group consisting of methyl, hydroxyl,carboxyl, and linear and branching alkyl groups; X is selected from thegroup consisting of ═O, —OH and —H; Y is selected from the groupconsisting of ═S and —SR₅, where R₅ is either hydrogen or an alkylgroup; and each of the bonds (a), (b), and (c) independently is either adouble or single bond, provided, however, that bond (a) and bond (b) arenot both double bonds.

In a preferred embodiment of the first aspect of the invention, in thecompound each R₁ is hydrogen; R₂ and R₃ are each hydrogen; R₄ is amethyl group; X is ═O; Y is ═S; bond (a) is a double bond; and bonds (b)and (c) are each single bonds.

In another embodiment, the acyl group of R₁ or R₃ is selected from thegroup consisting of:

In other embodiments, in the compound if R₁ is a hydrogen, then R₂ andR₃ are not each hydrogen; or R₄ is not a methyl group; or X is not ═O;or Y is not ═S; or bond (a) is not a double bond; or bonds (b) and (c)are not each single bonds. If R₂ is a hydrogen, then R₁ is a not ahydrogen, or R₃ is not a hydrogen; or R₄ is not a methyl group; or X isnot ═O; or Y is not ═S; or bond (a) is not a double bond; or bonds (b)and (c) are not each single bonds. If R₃ is a hydrogen, then R₁ is a nota hydrogen, or R₂ is not a hydrogen; or R₄ is not a methyl group; or Xis not ═O; or Y is not ═S; or bond (a) is not a double bond; or bonds(b) and (c) are not each single bonds. If R₄ is a methyl group, then R₁is a not a hydrogen, or R₂ and R₃ are not each not a hydrogen; or X isnot ═O; or Y is not ═S; or bond (a) is not a double bond; or bonds (b)and (c) are not each single bonds.

In other embodiments, if X is ═O, then R₁ is a not a hydrogen, or R₂ andR₃ are not each not a hydrogen; or R₄ is not a methyl group; or Y is not═S; or bond (a) is not a double bond; or bonds (b) and (c) are not eachsingle bonds. If Y is ═S, then R₁ is a not a hydrogen, or R₂ and R₃ arenot each not a hydrogen; or R₄ is not a methyl group; or X is not ═O; orbond (a) is not a double bond; or bonds (b) and (c) are not each singlebonds.

In yet other embodiments, if bond (a) is a double bond, then R₁ is a nota hydrogen, or R₂ and R₃ are not each not a hydrogen; or R₄ is not amethyl group; or X is not ═O; or Y is not ═S; or bonds (b) and (c) arenot each single bonds. If bond (b) is a single bond, then R₁ is a not ahydrogen, or R₂ and R₃ are not each not a hydrogen; or R₄ is not amethyl group; or X is not ═O; or Y is not ═S; bond (a) is not a doublebond or bond (c) is not a single bond. If bond (c) is a single bond,then R₁ is a not a hydrogen, or R₂ and R₃ are not each not a hydrogen;or R₄ is not a methyl group; or X is not ═O; or Y is not ═S; bond (a) isnot a double bond or bond (b) is not a single bond.

In a second aspect, the invention features a compound in apharmaceutically acceptable carrier, having the formula:

wherein each of X₁ and X₂ is independently selected from the groupconsisting of ═O, —OH and —H; R₁ is selected from the group consistingof hydrogen and hydroxyl; R₂ is selected from the group consisting ofhydrogen, sulfate, nitro, and halide; and the bond (a) is either asingle or double bond.

In a preferred embodiment of the second aspect of the invention, in thecompound each of X₁ and X₂ is ═O; R₁ is a hydroxyl group; R₂ is a nitrogroup; and the bond (a) is a double bond.

In other embodiments, if X₁ is ═O, then X₂ is not ═O; or R₁ is not ahydroxyl group; or R₂ is a not a nitro group; or the bond (a) is not adouble bond. If X₂ is ═O, then X₁ is not ═; or R₁ is not a hydroxylgroup; or R₂ is not a nitro group; or the bond (a) is not a double bond.If R₁ is a hydroxyl group, then each of X₁ and X₂ are not ═O; or R₂ is anot a nitro group; or the bond (a) is not a double bond. If R₂ is anitro group, then each of X₁ and X₂ are not ═O; or R₁ is not a hydroxylgroup; or the bond (a) is not a double bond. If the bond (a) is a doublebond, then each of X₁ and X₂ are not ═O; or R₁ is not a hydroxyl group;or R₂ is a not a nitro group; or the bond (a) is not a double bond.

In a third aspect, the invention features a chemical compound in apharmaceutically acceptable carrier, having the formula:

wherein each R₁ and R₂ is independently selected from the groupconsisting of hydrogen, amino, halide, and hydroxyl; R₃ is selected fromthe group consisting of hydrogen and methyl; and the bond (a) is eithera single or double bond.

In a preferred embodiment of the third aspect of the invention, in thecompound each R₁ is hydrogen; R₂ is fluorine; R₃ is a methyl group; andthe bond (a) is a double bond.

In other embodiments of the third aspect of the invention, if R₁ is ahydrogen, then R₂ is not fluorine; or R₃ is not a methyl group; or thebond (a) is not a double bond. If R₂ is a fluorine, then R₁ is nothydrogen; or R₃ is a not a methyl group; or the bond (a) is not a doublebond. If R₃ is a methyl group, then R₁ is not hydrogen, or R₂ is notfluorine; or the bond (a) is not a double bond. If the bond (a) is adouble bond, then R₁ is not hydrogen, or R₂ is not fluorine; or R₃ isnot a methyl group.

In a fourth aspect, the invention features a chemical compound in apharmaceutically acceptable carrier, having the formula:

wherein each R is independently selected from the group consisting of Hor CH₃; the bond (a) is either a single or double bond; the bond (b) iseither a single or double bond; and X is selected from the groupconsisting of ═O, —OH and —H.

In a preferred embodiment of the fourth aspect of the invention, in thecompound each R is CH₃; the bonds (a) and (b) are each a double bond;and X is ═O.

In other embodiments of the fourth aspect of the invention, if each R isCH₃, then the bonds (a) and (b) are not each a double bond; or X is not═O. If the double bond (a) is a double bond, then each R is not CH₃; orthe bond (b) is not a double bond; or X is not ═O. If the bond (b) is adouble bond, then each R is not CH₃; or the bond (a) is not a doublebond; or X is not ═O. If X is ═O, then R is not CH₃, or the bonds (a)and (b) are not each a double bond.

In a fifth aspect, the invention features a method for decreasingnecrosis, involving contacting a cell with a chemical compound havingthe formula:

wherein each R₁ is independently selected from the group consisting ofhydrogen, carboxy, methyl, hydroxyl, methoxyl, amino, and nitro; R₂ isselected from the group consisting of hydrogen, alkyl, and acyl; R₃ isselected from the group consisting of alkyl, acyl, halogen, hydrogen, orhydroxyl; R₄ is selected from the group consisting of methyl, hydroxyl,carboxyl, and linear and branching alkyl groups; X is selected from thegroup consisting of ═O, —OH and —H; Y is selected from the groupconsisting of ═S and —SR₅, where R₅ is either hydrogen or an alkylgroup; and each of the bonds (a), (b), and (c) independently is either adouble or single bond, provided, however, that bond (a) and bond (b) arenot both double bonds.

In a preferred embodiment of the fifth aspect of the invention, in thecompound each R₁ is hydrogen; R₂ and R₃ are each hydrogen; R₄ is amethyl group; X is ═O; Y is ═S; bond (a) is a double bond; and bonds (b)and (c) are each single bonds.

In another embodiment, the acyl group of R₁ or R₃ is selected from thegroup consisting of:

In other embodiments, in the compound if R₁ is a hydrogen, then R₂ andR₃ are not each hydrogen; or R is not a methyl group; or X is not ═O; orY is not ═S; or bond (a) is not a double bond; or bonds (b) and (c) arenot each single bonds. If R₂ is a hydrogen, then R₁ is a not a hydrogen,or R₃ is not a hydrogen; or R₄ is not a methyl group; or X is not ═O; orY is not ═S; or bond (a) is not a double bond; or bonds (b) and (c) arenot each single bonds. If R₃ is a hydrogen, then R₁ is a not a hydrogen,or R₂ is not a hydrogen; or R₄ is not a methyl group; or X is not ═O; orY is not ═S; or bond (a) is not a double bond; or bonds (b) and (c) arenot each single bonds. If R₄ is a methyl group, then R₁ is a not ahydrogen, or R₂ and R₃ are not each not a hydrogen; or X is not ═O; or Yis not ═S; or bond (a) is not a double bond; or bonds (b) and (c) arenot each single bonds.

In other embodiments, if X is ═O, then R₁ is a not a hydrogen, or R₂ andR₃ are not each not a hydrogen; or R₄ is not a methyl group; or Y is not═S; or bond (a) is not a double bond; or bonds (b) and (c) are not eachsingle bonds. If Y is ═S, then R₁ is a not a hydrogen, or R₂ and R₃ arenot each not a hydrogen; or R₄ is not a methyl group; or X is not ═O; orbond (a) is not a double bond; or bonds (b) and (c) are not each singlebonds.

In yet other embodiments, if bond (a) is a double bond, then R₁ is a nota hydrogen, or R₂ and R₃ are not each not a hydrogen; or R₄ is not amethyl group; or X is not ═O; or Y is not ═S; or bonds (b) and (c) arenot each single bonds. If bond (b) is a single bond, then R₁ is a not ahydrogen, or R₂ and R₃ are not each not a hydrogen; or R₄ is not amethyl group; or X is not ═O; or Y is not ═S; bond (a) is not a doublebond or bond (c) is not a single bond. If bond (c) is a single bond,then R₁ is a not a hydrogen, or R₂ and R₃ are not each not a hydrogen;or R₄ is not a methyl group; or X is not ═O; or Y is not ═S; bond (a) isnot a double bond or bond (b) is not a single bond.

In a sixth aspect, the invention features a method for decreasingnecrosis, involving contacting a cell with a chemical compound havingthe formula:

wherein each of X₁ and X₂ is independently selected from the groupconsisting of ═O, —OH and —H; R₁ is selected from the group consistingof hydrogen and a hydroxyl; R₂ is selected from the group consisting ofhydrogen, sulfate, nitro, and halide; and the bond (a) is either asingle or double bond.

In a preferred embodiment of the sixth aspect of the invention, in thecompound each of X₁ and X₂ is ═O; R₁ is a hydroxyl group; R₂ is a nitrogroup; and the bond (a) is a double bond.

In other preferred embodiments of the sixth aspect of the invention, ifX₁ is ═O, then X₂ is not ═O; or R₁ is not a hydroxyl group; or R₂ is anot a nitro group; or the bond (a) is not a double bond. If X₂ is ═O,then X₁ is not ═O; or R₁ is not a hydroxyl group; or R₂ is not a nitrogroup; or the bond (a) is not a double bond. If R₁ is a hydroxyl group,then each of X₁ and X₂ are not ═O; or R₂ is a not a nitro group; or thebond (a) is not a double bond. If R₂ is a nitro group, then each of X₁and X₂ are not ═O; or R₁ is not a hydroxyl group; or the bond (a) is nota double bond. If the bond (a) is a double bond, then each of X₁ and X₂are not ═O; or R₁ is not a hydroxyl group; or R₂ is a not a nitro group;or the bond (a) is not a double bond.

In a seventh aspect, the invention features a method for decreasingnecrosis, involving contacting a cell with a chemical compound havingthe formula:

wherein each R₁ and R₂ is independently selected from the groupconsisting of hydrogen, amino, halide, and hydroxyl; R₃ is selected fromthe group consisting of hydrogen and methyl; and the bond (a) is eithera single or double bond.

In a preferred embodiment of the seventh aspect of the invention, in thecompound each R₁ is hydrogen; R₂ is fluorine; R₃ is a methyl group; andthe bond (a) is a double bond.

In other embodiments of the seventh aspect of the invention, if R₁ is ahydrogen, then R₂ is not fluorine; or R₃ is not a methyl group; or thebond (a) is not a double bond. If R₂ is a fluorine, then R₁ is nothydrogen; or R₃ is a not a methyl group; or the bond (a) is not a doublebond. If R₃ is a methyl group, then R₁ is not hydrogen, or R₂ is notfluorine; or the bond (a) is not a double bond. If the bond (a) is adouble bond, then R₁ is not hydrogen, or R₂ is not fluorine; or R₃ isnot a methyl group.

In an eighth aspect, the invention features a method for decreasingnecrosis, involving contacting a cell with a chemical compound havingthe formula:

wherein each R is independently selected from the group consisting of Hor CH₃; the bond (a) is either a single or double bond; the bond (b) iseither a single or double bond; and X is selected from the groupconsisting of ═O, —OH and —H.

In a preferred embodiment of the eighth aspect of the invention, in thecompound each R is CH₃; the (a) and (b) bonds are each a double bond;and X is ═O.

In other embodiments of the eighth aspect of the invention, if each R isCH₃, then the bonds (a) and (b) are not each a double bond; or X is not═O. If the double bond (a) is a double bond, then each R is not CH₃; orthe bond (b) is not a double bond; or X is not ═O. If the bond (b) is adouble bond, then each R is not CH₃; or the bond (a) is not a doublebond; or X is not ═O. If X is ═O, then R is not CH₃, or the bonds (a)and (b) are not each a double bond.

In a preferred embodiment of any of the fifth, sixth, seventh, or eighthaspects of the invention, the cell is capable of undergoing necrosis inthe presence of zVAD-fmk and TNFα. In another preferred embodiment, thecell is capable of undergoing necrosis in the presence of zVAD-fmk andDMSO. In yet another preferred embodiment, the cell is mammalian, suchas a human or rodent cell. In yet another preferred embodiment, the cellis a neuron. In still another preferred embodiment, the compound is in apharmaceutically acceptable carrier.

In a ninth aspect, the invention features a method for treating acondition in a subject, involving the steps of administering a chemicalcompound having the formula:

to the subject, in a dosage sufficient to decrease necrosis, whereineach R₁ is independently selected from the group consisting of hydrogen,carboxy, methyl, hydroxyl, methoxyl, amino, and nitro; R₂ is selectedfrom the group consisting of hydrogen, alkyl, and acyl; R₃ is selectedfrom the group consisting of alkyl, acyl, halogen, hydrogen, orhydroxyl; R₄ is selected from the group consisting of methyl, hydroxyl,carboxyl, and linear and branching alkyl groups; X is selected from thegroup consisting of ═O, —OH and —H; Y is selected from the groupconsisting of═S and —SR₅, where R is either hydrogen or an alkyl group;and each of the bonds (a), (b), and (c) independently is either a doubleor single bond, provided, however, that bond (a) and bond (b) are notboth double bonds.

In a preferred embodiment of the ninth aspect of the invention, in thecompound each R₁ is hydrogen; R₂ and R₃ are each hydrogen; R₄ is amethyl group; X is ═O; Y is ═S; bond (a) is a double bond; and bonds (b)and (c) are each single bonds.

In another embodiment, the acyl group of R₁ or R₃ is selected from thegroup consisting of:

In other embodiments, in the compound if R₁ is a hydrogen, then R₂ andR₃ are not each hydrogen; or R₄ is not a methyl group; or X is not ═O;or Y is not ═S; or bond (a) is not a double bond; or bonds (b) and (c)are not each single bonds. If R₂ is a hydrogen, then R₁ is a not ahydrogen, or R₃ is not a hydrogen; or R₄ is not a methyl group; or X isnot ═O; or Y is not ═S; or bond (a) is not a double bond; or bonds (b)and (c) are not each single bonds. If R₃ is a hydrogen, then R₁ is a nota hydrogen, or R₂ is not a hydrogen; or R₄ is not a methyl group; or Xis not ═O; or Y is not ═S; or bond (a) is not a double bond; or bonds(b) and (c) are not each single bonds. If R₄ is a methyl group, then R₁is a not a hydrogen, or R₂ and R₃ are not each not a hydrogen; or X isnot ═O; or Y is not ═S; or bond (a) is not a double bond; or bonds (b)and (c) are not each single bonds.

In other embodiments, if X is ═O, then R₁ is a not a hydrogen, or R₂ andR₃ are not each not a hydrogen; or R₄ is not a methyl group; or Y is not═S; or bond (a) is not a double bond; or bonds (b) and (c) are not eachsingle bonds. If Y is ═S, then R₁ is a not a hydrogen, or R₂ and R₃ arenot each not a hydrogen; or R₄ is not a methyl group; or X is not ═O; orbond (a) is not a double bond; or bonds (b) and (c) are not each singlebonds.

In yet other embodiments, if bond (a) is a double bond, then R₁ is a nota hydrogen, or R₂ and R₃ are not each not a hydrogen; or R₄ is not amethyl group; or X is not ═O; or Y is not ═S; or bonds (b) and (c) arenot each single bonds. If bond (b) is a single bond, then R₁ is a not ahydrogen, or R₂ and R₃ are not each not a hydrogen; or R₄ is not amethyl group; or X is not ═O; or Y is not ═S; bond (a) is not a doublebond or bond (c) is not a single bond. If bond (c) is a single bond,then R₁ is a not a hydrogen, or R₂ and R₃ are not each not a hydrogen;or R₄ is not a methyl group; or X is not ═O; or Y is not ═S; bond (a) isnot a double bond or bond (b) is not a single bond.

In a tenth aspect, the invention features a method for treating acondition in a subject, involving the steps of administering a chemicalcompound having the formula:

to the subject, in a dosage sufficient to decrease necrosis, whereineach of X₁ and X₂ is independently selected from the group consisting of═O, —OH and —H; R₁ is selected from the group consisting of hydrogen anda hydroxyl; R₂ is selected from the group consisting of hydrogen,sulfate, nitro, and halide; and the bond (a) is either a single ordouble bond.

In a preferred embodiment of the tenth aspect of the invention, in thecompound each of X₁ and X₂ is ═O; R₁ is a hydroxyl group; R₂ is a nitrogroup; and the bond (a) is a double bond.

In other embodiments of the tenth aspect of the invention, if X₁ is ═O,then X₂ is not —O; or R₁ is not a hydroxyl group; or R₂ is a not a nitrogroup; or the bond (a) is not a double bond. If X₂ is ═O, then X₁ is not═O; or R₁ is not a hydroxyl group; or R₂ is not a nitro group; or thebond (a) is not a double bond. If R₁ is a hydroxyl group, then each ofX₁ and X₂ are not ═O; or R₂ is a not a nitro group; or the bond (a) isnot a double bond. If R₂ is a nitro group, then each of X₁ and X₂ arenot ═O; or R₁ is not a hydroxyl group; or the bond (a) is not a doublebond. If the bond (a) is a double bond, then each of X₁ and X₂ are not═O; or R₁ is not a hydroxyl group; or R₂ is a not a nitro group; or thebond (a) is not a double bond.

In an eleventh aspect, the invention features a method for treating acondition in a subject, involving the steps of administering a chemicalcompound having the formula:

to the subject, in a dosage sufficient to decrease necrosis, whereineach R₁ and R₂ is independently selected from the group consisting ofhydrogen, amino, halide, and hydroxyl; R₃ is selected from the groupconsisting of hydrogen and methyl; and the bond (a) is either a singleor double bond.

In a preferred embodiment of the eleventh aspect of the invention, inthe compound each R₁ is hydrogen; R₂ is fluorine; R₃ is a methyl group;and the bond (a) is a double bond.

In other embodiments of the eleventh aspect of the invention, if R₁ is ahydrogen, then R₁ is not fluorine; or R₃ is not a methyl group; or thebond (a) is not a double bond. If R₂ is a fluorine, then R₁ is nothydrogen; or R₃ is a not a methyl group; or the bond (a) is not a doublebond. If R₃ is a methyl group, then R₁ is not hydrogen, or R₂ is notfluorine; or the bond (a) is not a double bond. If the bond (a) is adouble bond, then R₁ is not hydrogen, or R₂ is not fluorine; or R₃ isnot a methyl group.

In a twelfth aspect, the invention features a method for treating acondition in a subject, involving the steps of administering a chemicalcompound having the formula:

to the subject, in a dosage sufficient to decrease necrosis, whereineach R is independently selected from the group consisting of H or CH₃;the bond (a) is either a single or double bond; the bond (b) is either asingle or double bond; and X is selected from the group consisting of═O, —OH and —H.

In a preferred embodiment of the twelfth aspect of the invention, in thecompound each R is CH₃; the (a) and (b) bonds are each a double bond;and X is ═O.

In other embodiments of the twelfth aspect of the invention, if each Ris CH₃, then the bonds (a) and (b) are not each a double bond; or X isnot ═O. If the double bond (a) is a double bond, then each R is not CH₃;or the bond (b) is not a double bond; or X is not ═O. If the bond (b) isa double bond, then each R is not CH₃; or the bond (a) is not a doublebond; or X is not ═O. If X is ═O, then R is not CH₃, or the bonds (a)and (b) are not each a double bond.

In a preferred embodiment of any of the ninth, tenth, eleventh, ortwelfth aspects of the invention, the condition is a neurodegenerativedisease. Most preferably the neurodegenerative disease is selected fromthe group consisting of Alzheimer's disease, Huntington's disease,cerebral ischemia, stroke, amyotropic lateral sclerosis, multiplesclerosis, Lewy body disease, Menkes, disease, Wilson disease,Creutzfeldt-Jakob disease, and Fahr disease. In other preferredembodiments, the condition is ischemic brain or heart injury, or headtrauma. In another preferred embodiment, the subject is a mammal, suchas a human or a rodent.

In a thirteenth aspect, the invention features a method for identifyinga compound that decreases necrosis, involving the steps of: providing acell in which apoptosis is prevented; contacting the cell with a firstcompound that causes a cell to undergo necrosis; contacting the cellwith a second compound; and measuring necrosis relative to a controlcell, wherein a decrease in necrosis indicates that the second compounddecreases necrosis.

In a preferred embodiment of the thirteenth aspect of the invention,apoptosis is prevented by contacting the cell with zVAD-fmk. In anotherpreferred embodiment, the first compound is TNFα or DMSO.

It will be appreciated that any of the R, X, or Y groups of thecompounds of the invention, or of the compounds used in any method ofthe invention may be alkyl derivatives or contain alkyl linkers.

As used herein, by “decreasing necrosis” is meant reducing the number ofcells which undergo necrosis relative to a control cell, receiving acell death stimulus, such as TNFα/zVAD-fmk or DMSO/zVAD-fmk without acandidate small molecule inhibitor. Preferably necrosis is decreased 10%relative to a control. More preferably necrosis is decreased 50%relative to a control. Most preferably necrosis is decreased 90%relative to a control. Preferably a decrease in necrosis is tested bydetermining the ATP level in a cell which has received a test compound,such as a compound from a chemical library, and comparing it to the ATPlevel in co a control cell. Necrosis is decreased in a cell treated witha test compound in which the ATP level does not decrease as much as itdoes in the control cell.

By “test compound” is meant a chemical, be it naturally-occurring orartificially-derived, that is surveyed for its ability to modulate thelevel of necrosis by employing one of the assay methods describedherein. Test compounds may include, for example, peptides, polypeptides,synthesized organic molecules, naturally occurring organic molecules,nucleic acid molecules, and components thereof.

By “cell death” is meant the death of a cell by either apoptosis ornecrosis.

As used herein, by “necrosis” is meant caspase-independent cell deathcharacterized by cellular ATP depletion. Preferably the cell is depletedof ATP 10% relative to a control cell, receiving vehicle only (forexample, DMSO). More preferably, the cell is depleted of ATP 50%relative to a control cell. Most preferably, the cell is depleted of ATP90% relative to a control cell. Preferably, necrosis is tested bydetermining the ATP level in a cell which has received a compound, forexample, zVAD-fmk, DMSO, or TNFα, and comparing it to the ATP level in acell receiving vehicle only. Necrosis occurs in a cell treated with atest compound in which the ATP level decreases relative to the controlcell.

Necrosis may be liquifactive, may affect adipose or hepatic tissue, andmay be caseous or fibrinoid. A cell may undergo necrosis in response toischemic cell injury or viral infection.

By “caspase-independent cell death” is meant cell death that occurs whenapoptosis is prevented. Apoptosis may be prevented by contacting a cellwith a caspase inhibitor such as zVAD-fmk at a concentration sufficientenough that the cell survives when stimulated to undergo apoptosis, forexample, by treatment with an apoptosis-promoting drug or ionizingradiation.

By “apoptosis” is meant cell death characterized by any of the followingproperties: nuclear condensation, DNA fragmentation, membrane blebbing,or cell shrinkage.

By “modulation of intracellular signaling pathways mediated by TNFα” ismeant a change in the communication between components of a cell inresponse to contacting the cell with TNFα. The change may be in the wayor duration in which proteins within the cell interact, or the way orduration in which proteins are altered, such as by phosphorylation ordephosphorylation, or in the way or duration in which proteins interactwith DNA.

By “modulation of intracellular signaling pathways mediated by DMSO” ismeant a change in the communication between components of a cell inresponse to contacting the cell with DMSO. The change may be in the wayor duration in which proteins within the cell interact, or the way orduration in which proteins are altered, such as by phosphorylation ordephosphorylation, or in the way or duration in which proteins interactwith DNA.

By “treating” is meant to submit or subject an animal, cell, lysate orextract derived from a cell, or a molecule derived from a cell to a testcompound that decreases necrosis.

By “condition” is meant a state of being or feeling. Conditions include,but are not limited to, neurodegenerative disease, stroke, liverdisease, pancreatic disease, ischemic brain or heart injury or otherischemic injuries, head trauma, a necrotic ulceration, septic shock,coronary heart disease, gastrointestinal disease, tuberculosis,alteration of blood vessels, viral infection (e.g., HIV infection orAIDS), or conditions associated with HIV infection or AIDS.

By “neurodegenerative disease” is meant a disease characterized byneuronal cell death. Examples of neurodegenerative diseases include, butare not limited to, Alzheimer's disease, Huntington's disease andrelated polyglutamine expansion diseases, cerebral ischemia, stroke,amyotropic lateral sclerosis, multiple sclerosis, Lewy body disease,Menkes disease, Wilson disease, Creutzfeldt-Jakob disease, and Fahrdisease.

By “neuron” is meant a cell of ectodermal embryonic origin derived fromany part of the nervous system of an animal. Neurons expresswell-characterized neuron-specific markers which include neurofilamentproteins, MAP2, and class III β-tubulin. Included as neurons are, forexample, hippocampal, cortical, midbrain dopaminergic, motor, sensory,sympathetic, septal cholinergic, and cerebellar neurons.

By a “dosage sufficient to decrease necrosis” is meant an amount of achemical compound or small molecule which when administered to a subjectwill decrease necrosis. Preferably necrosis is decreased in the subject10% relative to an untreated subject. More preferably necrosis isdecreased in the subject 50% relative to an untreated subject. Mostpreferably necrosis is decreased in the subject 90% relative to anuntreated subject.

As used herein, by “measuring necrosis” is meant determining if a cellis dying through necrosis, in the presence of a compound, compared to acell which is not in the presence of the compound (control cell).Necrosis can be measured by determining cellular ATP levels, wherein acell that is undergoing necrosis has a decreased level of cellular ATPcompared to a control cell. Necrosis may also be measured by stainingwith a vital dye, for example, trypan blue, wherein a cell which isnecrosing will be stained with the vital dye, and a cell which is notnecrosing will not be stained with the dye.

By a “derivative” is meant a structural derivative having a chemicalmodification of the compound which does not reduce the ultimate level ofnecrosis, but which does enhance bioavailability, solubility, orstability in vivo or ex vivo or which reduces the toxicity or dosagerequired. Such modifications are known to those skilled in the field ofmedicinal chemistry.

The present invention provides a number of advantages. For example, themethods described herein allow for a decrease in cell death occurringthrough a necrosis pathway. The invention also provides compounds andmethods for treating diseases in which necrosis occurs. These compoundsand methods can be used to treat conditions such as a neurodegenerativedisease, stroke, liver disease, pancreatic disease, ischemic heart orbrain injury or other ischemic injuries, head trauma, septic shock,coronary heart disease, gastrointestinal disease, tuberculosis,alteration of blood vessels, viral infection, such as HIV or AIDS, orconditions associated with a viral infection such as HIV or AIDS.

Other features and advantages of the invention will be apparent from thefollowing detailed description and from the claims.

BRIEF DESCRIPTION OF THE DRAWINGS

FIG. 1 is a schematic representation of the chemical structure of amolecule which may be used to decrease necrosis. In this chemicalstructure each R₁ is independently selected from the group consisting ofhydrogen, methyl, carboxy, hydroxyl, methoxyl, amino, and nitro; R₂ isselected from the group consisting of hydrogen, alkyl, and acyl; R₃ isselected from the group consisting of alkyl, acyl, halogen, hydrogen, orhydroxyl; R₄ is selected from the group consisting of methyl, hydroxyl,carboxyl, and linear and branching alkyl groups; X is selected from thegroup consisting of ═O, —OH and —H; Y is selected from the groupconsisting of ═S and —SR₅, where R₅ is either hydrogen or an alkylgroup; and each of the bonds (a), (b), and (c) independently is either adouble or single bond, provided, however, that bond (a) and bond (b) arenot both double bonds.

FIG. 2 is a schematic representation of the chemical structure ofchemical compound ID number 115807 from the ChemBridge chemical compoundlibrary.

FIG. 3 is a schematic representation of the chemical structure of amolecule which may be used to decrease necrosis. In this chemicalstructure, each of X₁ and X₂ is independently selected from the groupconsisting of ═O, —OH and —H; R₁ is selected from the group consistingof hydrogen and a hydroxyl; R₂ is selected from the group consisting ofhydrogen, sulfate, nitro, and halide; and the bond (a) is either asingle or double bond.

FIG. 4 is a schematic representation of the chemical structure ofchemical compound ID number 115681 from the ChemBridge chemical compoundlibrary.

FIG. 5 is a schematic representation of the chemical structure of amolecule which may be used to decrease necrosis. In this chemicalstructure each R₁ and R₂ is independently selected from the groupconsisting of hydrogen, amino, halide, and hydroxyl; R₃ is selected fromthe group consisting of hydrogen and methyl; and the bond (a) is eithera single or double bond.

FIG. 6 is a schematic representation of the chemical structure ofchemical compound ID number 210227 from the ChemBridge chemical compoundlibrary.

FIG. 7 is a schematic representation of the chemical structure of amolecule which may be used to decrease necrosis. In this chemicalstructure each R is independently selected from the group consisting ofH or CH₃; the bond (a) is either a single or double bond; the bond (b)is either a single or double bond; and X is selected from the groupconsisting of ═O, —OH and —H.

FIG. 8 is a schematic representation of the chemical structure ofchemical compound ID number 215686 from the ChemBridge chemical compoundlibrary.

DETAILED DESCRIPTION OF THE INVENTION

Described herein are methods for decreasing necrosis, as well as fortreating a condition in a subject. Techniques for carrying out themethods of the invention are now described in detail.

Identification of Chemical Compounds that Decrease Cell Necrosis

Assays that measure cell necrosis may be used to facilitate theidentification of molecules that decrease necrosis induced by stimuli,such as zVAD-fmk/TNFα. In one approach, zVAD-fmk is added to the culturemedia of cells at high density (for example, 5×10⁵ or 7.5×10⁵ cells/ml),which are capable of undergoing necrosis in response to zVAD-fmk TNFα.Candidate molecules, for example, chemical compounds from the ChemBridgechemical library are added, in varying concentrations to the cells, andthe cells are then exposed to TNFα.

The occurrence of necrosis of the treated cells is then measured, forexample, by measuring the cellular ATP level of the cells exposed tozVAD-TNFα (Crouch et al. J. Immunol. Methods 160:81-8, 1993;Storer etal. Mutat. Res. 368:59-101, 1996;and Cree et al. Toxicol. In Vitro11:553-556, 1997). The level of necrosis in the presence of thecandidate molecule is compared to the level of necrosis in the absenceof the candidate molecule, all other factors (e.g., cell type andculture conditions) being equal. The importance of zVAD-fmk in theinvention is to block cell death that may occur by apoptosis, so thatcell death by necrosis can be fully unmasked.

In a second approach, a cell may be exposed to a candidate molecule thatdecreases necrosis at the same time it is exposed to either zVAD-fmk orTNFα. In a third approach, a cell may be exposed to zVAD-fmk and TNFαfirst, and then to a candidate compound. The level of necrosis thatoccurs following each of these approaches is measured as describedabove.

The effect of candidate molecules on necrosis induced by cell deathstimuli, for example, zVAD-fmk/TNFα or zVAD-fmk/DMSO, may also bemeasured by other methods, for example, vital dye staining, using dyessuch as trypan blue or acridine orange/ethidium bromide.

Compounds that decrease necrosis may be purified or substantiallypurified, or may be one component of a mixture of compounds, such as apool of chemical compounds. In an assay of a mixture of compounds, theoccurrence of necrosis is tested against progressively smaller subsetsof the compound pool (e.g., produced by standard purification techniquessuch as HPLC or FPLC) until a single compound or minimal number ofeffective compounds is demonstrated to decrease necrosis. A moleculethat promotes a decrease in necrosis induced by zVAD-fmk/TNFα isconsidered particularly useful in the invention; such a molecule may beused, for example, as a therapeutic to decrease necrosis, in a patientwith a condition in which necrosis occurs, such as a neurodegenerativedisease.

Chemical compounds that are found, by the methods described above, toeffectively decrease necrosis induced, for example, by zVAD-fmk/TNFα inan in vitro system may be tested further in animal models. Particularlyuseful animal models include mouse and rat models of cell death,ischemic brain or heart injury or other ischemic injuries, head trauma,neurodegenerative diseases, coronary heart disease, and septic shock.Examples of such models include SOD or Huntington's disease genetransgenic mice, and other known models, such as those described by Liet al. (Hum. Mol. Genet. 8:1227-12236, 1999), Levine et al. (Neurosci.Res. 58:515-532, 1999), Vukosavic et al. (J. Neurochem. 73:2460-2468,1999), Gruney (J. Neurol. Sci. 152 suppl. 1: S67-73, 1997), Deshmukh etal. (Am. J. Physiol. 273 (4 Pt 1):C1130-1135, 1997), and Isibashi et al.(J. Immunol. 163:5666-5677, 1999). Compounds which demonstrate anability to decrease necrosis in in vivo models may be used astherapeutics to prevent necrosis, as appropriate.

Identification of Chemical Compounds that Decrease zVAD-fmk/DMSO InducedCell Necrosis

Methods for the identification of chemical compounds that decrease cellnecrosis induced, for example, by zVAD-fmk/DMSO at a low cell density(e.g., 1×10⁵ cells/ml) is achieved essentially as described above,except, the inducer of necrosis is zVAD-fmk/DMSO, rather thanzVAD-fmk/TNFα.

Structural, Derivatives of Chemical Compounds that Decrease Necrosis

The small molecules identified to decrease necrosis may be structurallymodified and subsequently used to decrease necrosis, or to treat asubject with a condition in which necrosis occurs. For example, thesmall molecules may be modified by any of the following processes:reduction of aliphatic double bonds; reduction of aliphatic ketones;substitution of nitro groups with protons, halides, or sulfates;reduction of C═O double bonds in flavone rings; elimination of oxygensattached to flavone rings; substitution of methoxyl groups with hydroxylgroups; attachment of hydroxyl and amino groups to benzyl rings;reduction of C═N double bonds; elimination of a fluoride or itssubstitution with a hydroxyl or other halide group; substitution of ahydrogen with an alkyl group; introduction of hydroxyl, methoxyl, amino,and nitro groups into the benzyl ring; reduction of the double bond inthe position 2 of the indol; introduction of double bonds in the linkerbetween indol and hydantoin moieties; reduction or alkylation of thethiourea moiety; reduction, alkylation, or acylation of the indol aminogroup; substitution of the hydantoin 3-methyl group with linear andbranching alkyl groups of varying length, and with hydroxyl, methyl, orcarboxyl functionalities; and reduction of the hydantoin ketone moiety.

The chemical compounds that decrease necrosis may be modified by one ofthe above processes or various combinations of the above processes. Themethods used to generate structural derivatives of the small moleculesthat decrease necrosis are readily known to those skilled in the fieldsof organic and medicinal chemistry.

Therapy

A compound identified as capable of decreasing necrosis, using any ofthe methods described herein, may be administered to patients or animalswith a pharmaceutically-acceptable diluent, carrier, or excipient, inunit dosage form. The chemical compounds for use in such therapies maybe produced and isolated by any standard technique known to those in thefield of medicinal chemistry. Conventional pharmaceutical practice maybe employed to provide suitable formulations or compositions toadminister the identified compound to patients suffering from a diseasein which necrosis occurs. Administration may begin before the patient issymptomatic.

Any appropriate route of administration may be employed. For example,the therapy may be administered either directly to the site of apredicted cell death event (for example, by injection) or systemically(for example, by any conventional administration technique).Administration of the compound may also be parenteral, intravenous,intraarterial, subcutaneous, intramuscular, intracranial, intraorbital,ophthalmalic, intraventricular, intracapsular, intraspinal,intracisternal, intraperitoneal, intranasal, aerosol, by suppositories,or oral administration. Therapeutic formulations may be in the form ofliquid solutions or suspensions; for oral administration, formulationsmay be in the form of tablets or capsules; and for intranasalformulations, in the form of powders, nasal drops, or aerosols. Thedosage of the therapeutic compounds in a pharmaceutically-acceptableformulation depends on a number of factors, including the size andhealth of the individual patient. The dosage to deliver may bedetermined by one skilled in the art.

Methods well known in the art for making formulations are found, forexample, in “Remington: The Science and Practice of Pharmacy” ((19thed.) ed. A. R. Gennaro A R., 1995, Mack Publishing Company, Easton,Pa.). Formulations for parenteral administration may, for example,contain excipients, sterile water, or saline, polyalkylene glycols suchas polyethylene glycol, oils of vegetable origin, or hydrogenatednapthalenes. Biocompatible, biodegradable lactide polymer,lactide/glycolide copolymer, or polyoxyethylene-polyoxypropylenecopolymers may be used to control the release of the compounds. Otherpotentially useful parenteral delivery systems for compounds thatdecreases necrosis include ethylene-vinyl acetate copolymer particles,osmotic pumps, implantable infusion systems, and liposomes. Formulationsfor inhalation may contain excipients, for example, lactose, or may beaqueous solutions containing, for example, polyoxyethylene-9-laurylether, glycocholate and deoxycholate, or may be oily solutions foradministration in the form of nasal drops, or as a gel.

The methods and compounds of the present invention may be used to treata number of diseases, as described above. Such methods and compounds maybe particularly useful in treating ischemic brain or heart injury orhead trauma. These diseases would be excellent targets of suchtherapies, as necrosis occurs in them.

If desired, treatment with a compound identified according to themethods described above, may be combined with more traditional therapiesfor a disease characterized by cell death, such as tacrine hydrochloridefor the treatment of Alzheimer's disease, or interferon β-1a for thetreatment of multiple sclerosis.

Preventative Anti-Necrosis Therapy

In a patient diagnosed with a heart disease (e.g., coronary heartdisease or ischemic heart injury) or degenerative disease (e.g., aneurodegenerative disease, such as Alzheimer's disease or Huntington'sdisease), any of the above therapies may be administered before theoccurrence of the disease phenotype. In particular, compounds shown todecrease necrosis may be administered by any standard dosage and routeof administration (as described above).

The methods of the instant invention may be used to decrease necrosis ofa cell or to treat disorders described herein in any mammal, forexample, humans, domestic pets, or livestock.

The following examples are provided to illustrate the invention. Theseexamples should not be construed as limiting.

EXAMPLE 1 Cells Undergo Necrosis in Response to zVAD-fmk and TNFα

The cell lines U-937 and BALB/c 3T3 were assayed for the occurrence ofnecrosis in response to the combined treatment of zVAD-fmk, a caspaseinhibitor, and TNFα, a cell death stimulator. The cells (5×10⁵ cells/ml)were exposed to zVAD-fmk (100 μM) and human TNFα (40 ng/ml) for 72hours. Induction of necrosis was assayed by measuring the cellular ATPlevels in response to TNFα (Crouch et al., supra, Storer et al. supra,and Cree et al. supra). Cells which underwent necrosis exhibiteddecreased cellular ATP levels relative to controls cells which receivedno treatment, zVAD-fmk (100 μM) alone, or human TNFα (40 ng/ml) alone.It was found that the cells underwent necrosis in response to treatmentwith zVAD-fmk and TNFα. The cells were also observed morphologically forthe occurrence of apoptosis or necrosis, for example, by analyzing thecells for membrane blebbing and nuclear condensation.

EXAMPLE 2 Identification of Small Molecules that Decrease Necrosis

The U-937 cell line was used to screen a library of 16,000 smallmolecule chemical compounds for a compound's ability to decreasenecrosis induced by exposure of the cell to zVAD-fmk and TNFα. Thelibrary of chemical compounds used in this screen were from ChemBridge(ChemBridge Corporation, San Diego Calif.).

In a primary screen, U-937 cells (5×10⁵ or 7.5×10⁵ cells/ml) were firstexposed to zVAD-fmk (100 μM). Thirty minutes later the same cells wereexposed to a chemical compound from the library (5 mg/ml, dissolved in0.1-0.5 μl of DMSO, giving a final DMSO concentration of 0.3% to 1.5%).After an additional thirty minutes, TNFα (40 ng/ml) was added to thecell culture medium. The cells were then incubated at 37° C. for 72hours, and were then assayed for cellular ATP levels. Compounds whichdid not prevent a decrease in cellular ATP levels were compounds whichdid not prevent necrosis in response to treatment of the cell withzVAD-fmk and TNFα. Compounds which maintained cellular ATP levels werecompounds which blocked necrosis triggered by zVAD-fmk and TNFα.

As a result of the primary screen, 50 chemical compounds from thelibrary were identified to decrease necrosis induced by zVAD-fmk andTNFα. These compounds were selected for a second round of screening forcompounds that decrease necrosis induced by zVAD-fmk and TNFα.

In a secondary screen, the compounds identified from the first screen,above, to decrease necrosis induced by zVAD-fmk and TNFα were assayedfor their potency. Serial dilution of each chemical compound wasperformed and the compounds were administered to U-937 cells, as per theprimary screen. The concentrations of each compound were 70 μM, 23 μM, 8μM, and 2.5 μM. The level of necrosis occurring in response to zVAD-fmk,TNFα, and the various concentrations of chemical compounds was assayedas described above for the primary screen.

As a result of the secondary screen, four chemical compounds from theChemBridge library: 115807, 115681, 210227, and 215686 were identifiedto decrease necrosis in response to exposure of the cell to zVAD-fmk andTNFα.

EXAMPLE 3 Cells are Protected from Necrosis Upon Exposure to zVAD-fmkand DMSO

Exposure of low density U-937 cells (1×10⁵ cells/ml) to zVAD-fmk (100μM) and DMSO (0.5%) for 72 hours results in cell death by necrosis. Thecompounds identified to decrease cell necrosis triggered by zVAD-fmk andTNFα, compounds 115807, 115681, 210227, and 215686 from the ChemBridgechemical library, were also evaluated for their ability to decrease cellnecrosis induced by zVAD-fmk and DMSO. The cells (1×10⁵ cells/ml) werefirst exposed to zVAD-fmk, and then thirty minutes later to theabove-identified small molecules that decrease necrosis. After anadditional 30 minutes, the cells were exposed to DMSO. Seventy-two hoursafter exposure to the compounds, cellular ATP levels were measured, asdescribed above. All four chemical compounds that decreased necrosisinduced by zVAD-fmk/TNFα also decreased necrosis induced byzVAD-fmk/DMSO.

EXAMPLE 4 The Role of Fas-associated Death Domain Protein inzVADfmk/TNFα- or zVAD-fmk/DMSO-induced Necrosis

A cell expressing a dominant negative form of the protein Fas-associateddeath domain (FADD) can also prevent a cell from undergoing necrosis inresponse to treatment with zVAD-fmk/TNFα- or zVAD-fmk/DMSO. Jurkat cellswere stably transfected with a FADD-FKBP fusion construct (Kawahara A.et al. J. Cell Biol. 143(5):1353-60, 1998). Normally such cells undergoapoptosis when FADD is multimerized. However, these cells, in thepresence of the caspase inhibitor zVAD-fmk, are protected fromapoptosis, and instead undergo necrosis, thus establishing thedependence of apoptosis in this system on caspase activity and inductionof necrosis in the absence of caspases.

The stably transfected Jurkat cells (500,000 cells/ml) were treated with100 nM of FKBP dimerizer (Arraid Pharmaceuticals; used to stimulate FADDmultimerization) in the presence of 100 μM of zVAD-fmk (pre-treated for1 hour) and compounds from the library identified to decrease necrosis(dissolved in DMSO to give a final DMSO concentration of 0.5%; added 30minutes after zVAD-fmk) for 48 hours. Cell viability was then assessedby measuring cellular ATP levels. The small molecules providedprotection from necrosis induced in the presence of zVAD-fmk, but notfrom apoptosis induced by FADD dimerization in the absence of zVAD-fmk.These results indicate that FADD may be involved in mediating necrosisin response to zVAD-fmk/TNFα- or zVAD-fmk/DMSO. It is possible that thesmall molecules that decrease necrosis may function by interacting withFADD and disrupting FADD's normal function of promoting necrosis upontreatment of a cell with zVAD-fmk/TNFα- or zVAD-fmk/DMSO.

EXAMPLE 5 Identification of Intracellular Targets of Small Moleculesthat Decrease Necrosis

Molecules within a cell that interact with the small molecule compoundsthat decrease necrosis can be identified using a number of differentstrategies. Each strategy involves detecting interactions betweenvarious proteins from a cell and a small molecule that decreasesnecrosis, identified according to the methods described above. Toidentify proteins that interact with a small molecule that decreasesnecrosis, the small molecule may be bound to a bead, using methods knownto those skilled in the art. Each strategy should be carried out usingproteins from cells which have been exposed to zVAD-fmk/TNFα- orzVAD-fmk/DMSO.

In one strategy, the signaling complex containing FADD, among otherproteins, may be immunoprecipitated, using standard techniques known tothose skilled in the art. This complex may then be added to the beadscontaining the desired small molecule compound that decreases necrosis.Proteins that interact with the small molecule that decreases necrosismay be identified by Western blot detection of proteins contained in thecomplex, or other techniques known to those skilled in the field ofmolecular biology. Any detected binding interactions indicate that thetarget of the small molecule that decreases necrosis is present in theimmunoprecipitated FADD complex.

In a second strategy for identifying targets of a small molecule thatdecreases necrosis, a cell may be fractionated, and the variousfractionated pools may be assayed for interaction with the chemicalcompound using standard molecular biology techniques. A pool of proteinswhich interacts with the small molecule that decreases necrosisindicates that the pool contains a protein that is a target of the smallmolecule that decreases necrosis. The target of the small molecule thatdecreases necrosis may be isolated using techniques known to thoseskilled in the art.

A third strategy involves small pool expression screening systems.Targets of a small molecule that decreases necrosis can be identifiedfrom any cell in which the small molecule protects cells from necrosistriggered by zVAD-fmk/TNFα- or zVAD-fmk/DMSO. This method foridentifying targets of small molecules that decrease necrosis can bedone, for example, according to the methods of Lustig et al. (Methods inEnzymology 283:83-99, 1997). In this method a cDNA library is made froma desired cell line, or any other desired source. The cDNA library isthen divided into pools of 100 clones, and the cDNAs are transcribed andtranslated to form proteins pools for the detection of interactionsbetween a protein and a small molecule that decreases necrosis.Interactions between the small molecules that decrease necrosis andpools of library proteins can be detected using standard molecularbiology techniques, for example, SDS-PAGE.

EXAMPLE 6 Structural Derivatives of Small Molecules that DecreaseNecrosis

The following modifications of the small molecules that decreasenecrosis may be made and evaluated for their efficacy in decreasingnecrosis, for example, that induced by zVAD-fmk/TNFα or zVAD-fmk/DMSO.

The chemical compound 115807 may be modified by the introduction of ahydroxyl, methyl, carboxy, methoxyl, amino or nitro group into thebenzyl ring (for example, at any or all of the R₁ positions of FIG. 1).Double bonds may be introduced in the linker between indol and hydantoinmoieties (for example, in FIG. 1, bonds (a), (b), or (c) may be doublebonds, provided that not both bonds (a) and (b) are double bonds). Thethiourea moiety may be reduced or alkylated (for example, the moiety maybe —SH or SR₅, wherein R₅ is an alkyl group). The indol amino group maybe reduced, alkylated, or acylated (for example, in FIG. 1, R₂ may beCH3, CH₃(CH₂)_(n), where n is between 1 and 4 and, HOOC—(CH₂)_(n), wheren is between 1 and 4,

In addition, the hydantoin 3-methyl group may be substituted with linearor branching alkyl groups of varying length, and with hydroxyl, methyl,or acyl functionalities (for example the following groups may be presentat the R₄ position of FIG. 1; CH₃, CH₃(CH₂)_(n) where n is between 1 and4, OH, or HOOC—(CH₂)_(n)—, wherein n is between 1 and 4. In addition,the linker CH₂ group between the indol and hydantoin moieties can bealkylated, acylated, halogenated, or hydroxylated (for example, in FIG.1, R₄ may be CH₃, CH₃(CH₂)_(n), where n is between 1 and 4,HOOC—(CH₂)_(n), where n is between 1 and 4,

Lastly, the hydantoin ketone moiety may be reduced to a hydroxyl groupor a hydrogen.

The chemical compound 210227 may be modified by the attachment of ahalide, or hydroxyl or amino groups to either or both of the benzylrings (for example, in the R₁ or R₂ positions of FIG. 5). The C═N doublebond may be reduced, or the fluoride may be eliminated or substitutedwith a hydroxyl group or other halide.

The chemical compound 215686 may be modified by reducing the two centralaliphatic double bonds, together, or each one individually. The ketonemay also be reduced, or the methoxyl groups may be substituted withhydroxyl groups, each individually, or together.

The chemical compound 115681 may be modified in the following ways. Thealiphatic double bond or the aliphatic ketone may be may be reduced. Thenitro group may be substituted with a proton, halide, or sulfate. TheC═O double bond in the flavone ring may be reduced. Either one or two ofthe oxygens attached to the flavone may also be eliminated.

What is claimed is:
 1. A method for decreasing necrosis in a subject ina with a disease or condition selected from the group consisting of:Alzheimer's disease, Huntington's disease, cerebral ischemia, stroke,amyotropic lateral sclerosis, multiple sclerosis, Lewy body disease,Menke's disease, Wilson disease, Creutzfeldt-Jakob disease, and Fahrdisease, said method comprising treating a cell with a chemical compoundof the formula:

wherein each R₁ is independently selected from the group consisting ofhydrogen methyl, carboxy, hydroxyl, methyl, amino, and nitro; R₂ isselected from the group consisting of hydrogen, alkyl, and acyl; R₃ isselected from the group consisting of alkyl, acyl, halogen, hydrogen,and hydroxyl; R₄ is selected from the group consisting of methyl,hydroxyl, carboxyl, and linear and branching alkyl groups; and each ofthe bonds (a), (b), and (c) independently is either a double or singlebond, provided, however, that bond (a) and bond (b) are not both doublebonds.
 2. The method of claim 1, wherein said compound is selected fromthe group consisting of:


3. The method of claim 1, wherein said cell is capable of undergoingnecrosis in the presence of zVAD-fmk and TNF.
 4. The method of claim 1,wherein said cell is capable of undergoing necrosis in the presence ofzVAD-fmk and DMSO.
 5. The method of claim 1, wherein said cell ismammalian.
 6. The method of claim 1, wherein said cell is human.
 7. Themethod of claim 1, wherein said cell is a neuron.
 8. The method of claim1, wherein said cell is a rodent cell.
 9. The method of claim 1, whereinsaid compound is in a pharmaceutically acceptable carrier.
 10. A methodfor treating a subject with a condition selected from the groupconsisting of: Alzheimer's disease, Huntington's disease, cerebralischemia, stroke, amyotropic lateral sclerosis, multiple sclerosis, Lewybody disease, Menke's disease, Wilson disease, Creutzfeldt-Jakobdisease, and Fahr disease, wherein decreasing necrosis is of benefit,said method comprising administering to said subject a chemical havingthe formula;

wherein each R₁ is independently selected from the group consisting ofhydrogen, methyl, carboxy, hydroxyl, methoxyl, amino, and nitro; R₂ isselected from the group consisting of hydrogen, alkyl, and acyl; R₃ isselected from the group consisting of alkyl, acyl, halogen, hydrogen,and hydroxyl; R₄ is selected from the group consisting of methyl,hydroxyl, carboxyl, and linear and branching alkyl groups; and each ofthe bonds (a), (b), and (c) independently is either a double or singlebond, provided, however, that bond (a) and bond (b) are not both doublebonds.
 11. The method of claim 10, wherein said subject is selected fromthe group consisting of:


12. The method of claim 10, wherein said subject is a mammal.
 13. Themethod of claim 12, wherein said subject is a human.
 14. The method ofclaim 12, wherein said subject is a rodent.
 15. A method for treating asubject with a disease or condition selected from the group consistingof: a liver disease, a pancreatic disease, an ischemic brain injury, anischemic heart injury, an ischemic injury to non-cardiac and non-neuraltissue, a head trauma, a necrotic ulceration, septic shock, coronaryheart disease, a gastrointestinal disease, tuberculosis, a viralinfection, and conditions associated with HIV infection or AIDS, saidmethod comprising treating a cell with a chemical compound of theformula;

wherein each R₁ is independently selected from the group consisting ofhydrogen, methyl, carboxy, hydroxyl, methoxyl, and nitro; R₂ is selectedfrom the group consisting of hydrogen, alkly, and acyl; R₃ is selectedfrom the group consisting of alkyl, acyl, hydrogen, and hydroxyl; R₄ isselected from the group consisting of methyl, hydoxyl, carboxyl, andlinear and branching alkyl groups; and each of the bonds (a), (b), and(c) independently is either a double or single bond, provided, however,that bond (a) and bond (b) are not both double bonds.
 16. A method fordecreasing necrosis in a subject with a disease or condition selectedfrom the group consisting of: a liver disease, a pancreatic disease, anischemic brain injury, an ischemic heart injury, an ischemic injury tonon-cardiac and non-neural tissue, a head trauma, a necrotic ulceration,septic shock, coronary heart disease, a gastrointestinal disease,tuberculosis, a viral infection, and conditions associated with HIVinfection or AIDS, wherein decreasing necrosis is of benefit, saidmethod comprising administering to said subject a chemical compoundhaving the formula;

wherein each R₁ is independently selected from the group consisting ofhydrogen, methyl, carboxy, hydroxyl, methoxyl, amino, and nitro; R₂ isselected from the group consisting of hydrogen, alyl, and acyl; R₃ isselected from the group consisting of alkyl, acyl, halogen, hydrogen,and hydroxyl; R₄ is selected from the group consisting of methyl,hydroxyl, carboxyl, and linear and branching alkyl groups; and each ofthe bonds (a), (b), and (c) independently is either a double or singlebond, provided, however, that bond (a) and bond (b) are not both doublebonds.